ABUS
Price
$4.85
Change
-$0.03 (-0.61%)
Updated
Sep 25 closing price
Capitalization
960.81M
46 days until earnings call
Intraday BUY SELL Signals
ARRY
Price
$4.03
Change
+$0.10 (+2.54%)
Updated
Sep 25 closing price
Capitalization
620.65M
40 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABUS vs ARRY

ABUS vs ARRY Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABUS vs. ARRY commentary
Sep 27, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a StrongBuy and ARRY is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
ABUS vs ARRY: Fundamental Ratings
ABUS
ARRY
OUTLOOK RATING
1..100
6611
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
99
Overvalued
PROFIT vs RISK RATING
1..100
67100
SMR RATING
1..100
15100
PRICE GROWTH RATING
1..100
4888
P/E GROWTH RATING
1..100
2423
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABUS's Valuation (61) in the Biotechnology industry is somewhat better than the same rating for ARRY (99). This means that ABUS’s stock grew somewhat faster than ARRY’s over the last 12 months.

ABUS's Profit vs Risk Rating (67) in the Biotechnology industry is somewhat better than the same rating for ARRY (100). This means that ABUS’s stock grew somewhat faster than ARRY’s over the last 12 months.

ABUS's SMR Rating (15) in the Biotechnology industry is significantly better than the same rating for ARRY (100). This means that ABUS’s stock grew significantly faster than ARRY’s over the last 12 months.

ABUS's Price Growth Rating (48) in the Biotechnology industry is somewhat better than the same rating for ARRY (88). This means that ABUS’s stock grew somewhat faster than ARRY’s over the last 12 months.

ARRY's P/E Growth Rating (23) in the Biotechnology industry is in the same range as ABUS (24). This means that ARRY’s stock grew similarly to ABUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABUSARRY
RSI
ODDS (%)
Bearish Trend 2 days ago
63%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 19 days ago
74%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 6 days ago
76%
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
87%
Aroon
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
81%
COMPARISON
Comparison
Sep 27, 2026
Stock price -- (ABUS: $4.85 vs. ARRY: $4.03)
Brand notoriety: ABUS and ARRY are both not notable
ABUS represents the Biotechnology, while ARRY is part of the Alternative Power Generation industry
Current volume relative to the 65-day Moving Average: ABUS: 199% vs. ARRY: 78%
Market capitalization -- ABUS: $960.81M vs. ARRY: $620.65M
ABUS [@Biotechnology] is valued at $960.81M. ARRY’s [@Alternative Power Generation] market capitalization is $620.65M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.37B. The market cap for tickers in the [@Alternative Power Generation] industry ranges from $3.39K to $270.64B. The average market capitalization across the [@Biotechnology] industry is $2.21B. The average market capitalization across the [@Alternative Power Generation] industry is $1.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 2 FA rating(s) are green while ARRY’s FA Score has 1 green FA rating(s).

  • ABUS’s FA Score: 2 green, 3 red.
  • ARRY’s FA Score: 1 green, 4 red.
According to our system of comparison, ABUS is a better buy in the long-term than ARRY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 4 TA indicator(s) are bullish while ARRY’s TA Score has 4 bullish TA indicator(s).

  • ABUS’s TA Score: 4 bullish, 4 bearish.
  • ARRY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ABUS and ARRY are a good buy in the short-term.

Price Growth

ABUS (@Biotechnology) experienced а -3.19% price change this week, while ARRY (@Alternative Power Generation) price change was -0.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.17%. For the same industry, the average monthly price growth was -13.24%, and the average quarterly price growth was +5.35%.

The average weekly price growth across all stocks in the @Alternative Power Generation industry was +0.60%. For the same industry, the average monthly price growth was -8.01%, and the average quarterly price growth was -38.02%.

Reported Earning Dates

ABUS is expected to report earnings on Nov 11, 2026.

ARRY is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-4.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Alternative Power Generation (+0.60% weekly)

The alternative power generation industry consists of companies that operate power facilities converting non-conventional forms of energy into electricity. These energy forms are alternatives to fossil fuels, and many of them are derived from natural resources. Alternative energy forms include solar, wind, hydro, and geothermal steam. A major purpose behind using alternative energy – also called ‘clean’ energy - is to address concerns related to the more conventional fossil fuels, such as the latter’s high carbon dioxide emissions which is often considered a factor in global warming. Alternative power generation has been gaining traction in recent years, and could grow further in the future. Large organizations like Google have invested substantially in wind and solar energy-powered electricity. Some of the prominent U.S. companies operating in the alternative power generation industry includes Ormat Technologies, Inc., TerraForm Power, Inc. and NextEra Energy Partners LP.

View a ticker or compare two or three
ABUS
Daily Signal:
Gain/Loss:
ARRY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MCHP78.694.00
+5.36%
Microchip Technology
HPAI0.310.01
+4.31%
Helport AI Limited
SLBT1.570.01
+0.64%
SL Science Holding Limited
MNSB24.83-0.03
-0.12%
MainStreet Bancshares
CVSA120.75-3.41
-2.75%
Covista Inc.

ABUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with ARRY. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then ARRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
-0.61%
ARRY - ABUS
43%
Loosely correlated
+2.54%
AXON - ABUS
42%
Loosely correlated
-3.35%
KURA - ABUS
42%
Loosely correlated
-0.92%
MGTX - ABUS
42%
Loosely correlated
-1.27%
RCKT - ABUS
42%
Loosely correlated
-3.53%
More

ARRY and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARRY has been loosely correlated with NXT. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if ARRY jumps, then NXT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARRY
1D Price
Change %
ARRY100%
+2.54%
NXT - ARRY
65%
Loosely correlated
+1.10%
SHLS - ARRY
59%
Loosely correlated
+0.27%
AXON - ARRY
53%
Loosely correlated
-3.35%
INO - ARRY
52%
Loosely correlated
-2.48%
ENPH - ARRY
50%
Loosely correlated
-1.28%
More